A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Sotatercept (Primary) ; Ruxolitinib
- Indications Anaemia; Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 06 Dec 2016 Preliminary results (n=18) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 05 Dec 2016 Preliminary results published in the Acceleron Pharma and Celgene Corporation Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History